Association study of the INPP1, 5HTT, BDNF, AP-2β and GSK-3β GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder

Michelon, Leandro; Meira-Lima, Ivanor; Cordeiro, Quirino; Miguita, Karen; Breen, Gerome; Collier, David; Vallada, Homero

doi:10.1016/j.neulet.2006.05.001

Cited by 96 publications

(75 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore it is somewhat surprising that most studies have not found general associations between variants in this gene and BPD, or the response to lithium. Two studies find that an identified SNP in the promoter of this gene (−50 T to C) does not appear to be related to the degree of prophylactic lithium response in bipolar patients (Michelon et al, 2006;Szczepankiewicz et al, 2006a). Furthermore, one genetic study failed to find any significant association between two SNPs (−1727 A to T, and −50 T to C) in GSK3β with BPD or schizophrenia in a Korean population (Lee et al, 2006).…”

Section: Human Genetic Studiesmentioning

confidence: 99%

Circadian genes, rhythms and the biology of mood disorders

McClung

2007

Pharmacology & Therapeutics

572

382

View full text Add to dashboard Cite

For many years, researchers have suggested that abnormalities in circadian rhythms may underlie the development of mood disorders such as bipolar disorder, major depression and seasonal affective disorder. Furthermore, some of the treatments that are currently employed to treat mood disorders are thought to act by shifting or "resetting" the circadian clock, including total sleep deprivation and bright light therapy. There is also reason to suspect that many of the mood stabilizers and antidepressants used to treat these disorders may derive at least some of their therapeutic efficacy by affecting the circadian clock. Recent genetic, molecular and behavioral studies implicate individual genes that make up the clock in mood regulation. As well, important functions of these genes in brain regions and neurotransmitter systems associated with mood regulation is becoming apparent. In this review, the evidence linking circadian rhythms and mood disorders, and what is known about the underlying biology of this association, is presented.

show abstract

Section: Human Genetic Studiesmentioning

confidence: 99%

Circadian genes, rhythms and the biology of mood disorders

McClung

2007

Pharmacology & Therapeutics

572

382

View full text Add to dashboard Cite

show abstract

“…Two studies reported that excellent response was found in patients who carried particular variants in BDNF [DmitrzakWeglarz et al 2008;Rybakowski et al 2005]. However, Masui and colleagues had negative findings in a Japanese sample [Masui et al 2006b], and Michelon and colleagues' results were also negative [Michelon et al 2006]. Another study found modest evidence implicating the BDNF receptor gene NTRK2 in lithium response, though the association was seen only for patients with a subtype of illness [Bremer et al 2007].…”

Section: Bipolar Disordermentioning

confidence: 99%

Predictors of lithium response in bipolar disorder

Tighe

Mahon

Potash

2011

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

While lithium is generally regarded as the first-line agent for patients with bipolar disorder, it does not work for everyone, which raises the question: can we predict who will be most likely to respond? In this paper, we review the most compelling clinical, biologic, and genetic predictors of lithium response in bipolar disorder. Among clinical factors, the strongest predictors of good response are fewer hospitalizations preceding treatment, an episodic course characterized by an illness pattern of mania followed by depression, and a later age at onset of bipolar disorder. While several biologic predictors have been studied, the results are preliminary and require replication with studies of larger patient samples over longer observation periods. Neuroimaging is a particularly promising method given that it might concurrently illuminate pathophysiologic underpinnings of bipolar disorder, the mechanism of action of lithium, and potential predictors of lithium response. The first genome-wide association study of lithium response was recently completed. No definitive results emerged, perhaps because the study was underpowered. With major new initiatives in progress aiming to identify genes and genetic variations associated with lithium response, there is much reason to be hopeful that clinically useful information might be generated within the next several years. This could ultimately translate into tests that could guide the choice of mood-stabilizing medication for patients. In addition, it might facilitate pharmacologic research aimed at developing newer, more effective medications that might act more quickly and yield fewer side effects.

show abstract

“…68 In another study, Michelon et al found that the polymorphisms of the SLC6A4, glycogen synthase kinase-3beta, inositol polyphosphatase 1-phosphate, brain-derived neurotrophic factor and activator protein 2beta genes are not predictive factors for lithium prophylactic response in a sample of BPD type I patients. 69 Challenges for the improvement of psychiatric genetic studies in Brazil 1. Financial support Despite of the development of investigations on psychiatric genetics in Brazil, the researchers have faced some important challenges.…”

Section: Research Groups and Their Main Findings In The Brazilian Popmentioning

confidence: 99%